The phone calls started coming faster after May 13th. Hospice operators. Home health agencies. Behavioral health clinics that had been coasting on documentation practices they'd used for years suddenly wondering if every clinical note could become a legal landmine.
Brellium, a five-year-old New York startup that uses AI to audit medical charts before they reach insurance companies, had built exactly the tool for that moment—perhaps more prescient timing than even its founders anticipated. By July of last year, according to an investor update from Euclid Ventures, the company had raised north of $30 million in total funding across multiple rounds. Its customer base: more than 250,000 healthcare providers now operating under some of the most aggressive federal scrutiny the industry has seen in a decade.
The catalyst wasn't subtle. In May 2026, according to CMS's press release, the Centers for Medicare & Medicaid Services did something it rarely does—impose a nationwide enrollment freeze. For six months, no new hospice or home health agencies could enter the Medicare system. CMS framed it as an "aggressive crackdown" on fraud. What it actually meant: documentation suddenly mattered in ways back-office compliance teams had never quite internalized.
Money Follows Fear
Brellium raised $16.7 million in April 2025, led by First Round Capital and Left Lane Capital, with backing from Menlo Ventures, Digital Health Venture Partners, Kearny Jackson, and Necessary Ventures. Notable angels included Headway CEO Andrew Adams and a handful of digital health founders who'd presumably wrestled with similar compliance headaches.
The jump to $30 million-plus by mid-2026 appears documented only in secondary commentary from existing investors. The company's own newsroom hasn't announced another formal raise, which leaves open the question of whether that figure reflects additional venture rounds, debt facilities, or some combination. (A company spokesperson did not respond to requests for clarification on the funding structure.)
What's clearer: the market Brellium is chasing has gotten meaningfully larger, and considerably more anxious.
The Documentation Reckoning
Federal auditors have been scrutinizing documentation practices, as seen in the December 2024 Office of Inspector General review that flagged Indiana's Medicaid program for at least $56 million in improper payments tied to applied behavior analysis services—the majority stemming from inadequate documentation. Maine's audit, released two months later, echoed similar problems. These weren't isolated incidents. They were breadcrumbs pointing toward a broader reckoning.
The company's pitch is straightforward, if audacious: Brellium audits every clinical chart in near real-time, checking compliance against payer requirements, state regulations, and quality benchmarks. If something's wrong, providers get flagged before the bill goes out. And if a payer later claws back money on a chart Brellium certified as compliant? The company states it will cover the cost—a guarantee that sounds either confident or reckless depending on how good the AI actually is.
Founded in 2021 by Zach Rosen, Henry Kasa, Max Katzman, and Alex Le-Tu, Brellium now claims to process over a million clinical records each month. According to the company's own reports, its customer roster includes Rula, Headspace, Grow Therapy, Hopebridge, Lightfully Behavioral Health, and Talkiatry—a cross-section of behavioral health's recent venture-backed surge.
Positioning for the Squeeze
Brellium has announced strategic moves into targeted sectors since its Series A round. In May 2026, it secured CHAP VERIFIED status for its hospice AI auditing tools—a stamp of approval that matters in an industry where accreditation carries weight. The following month came an executive partnership with the National Partnership for Healthcare and Hospice Innovation, a trade group representing precisely the operators now sweating the CMS moratorium.
Strategic hires tell part of the story. Dr. Andrey Ostrovsky, formerly Medicaid's Chief Medical Officer under the Obama administration, joined as an advisor in May 2026. It's the kind of move that signals either deep regulatory sophistication or a keen sense of which résumés open doors—probably both.
The company has also built integrations with athenahealth's marketplace, along with newer platforms like Upheal, Opus, and Passage Health. The goal seems to be embedding Brellium as a compliance layer atop existing electronic health record systems rather than forcing providers to rip out infrastructure they've already spent years implementing.
What the Moratorium Changed
The CMS enrollment freeze, now extended through at least November 2026, did more than pause new market entrants. It sent a signal: the era of lax documentation enforcement is over, and the cost of getting it wrong has escalated sharply. For thousands of hospice and home health agencies, that means revisiting every chart with a level of scrutiny that might have seemed paranoid two years ago.
Whether this regulatory intensity represents a permanent reset or just another pendulum swing is anyone's guess. Federal enforcement tends to move in cycles—periods of aggressive auditing followed by quieter stretches as attention shifts elsewhere. But for now, providers across behavioral health, hospice, and home health are acting like the auditors aren't going away anytime soon.
Brellium, for its part, seems content to ride that wave as far as it will go. In an industry where fear is often a more reliable motivator than ambition, the company has found its moment. How long it lasts—and whether the AI actually delivers on its promises when the audit letters arrive—remains to be seen.
